Erasca prices a $550M follow-on offering at $17.50, a slim 2.2% discount to the last sale

summarizeSummary

Erasca prices a 31.4-million-share follow-on offering at $17.50, raising $550 million (up to $632.5 million with greenshoe) to fund its oncology pipeline. The deal prices at a slim 2.2% discount to the last sale, reflecting strong demand on the heels of positive ERAS-0015 data.

check_boxKey Events · Financing and Capital Events · ERAS

• Follow-On Offering Priced at $17.50

  Erasca is selling 31,428,572 shares at $17.50 per share, a 2.2% discount to the July 13 close of $17.90, for gross proceeds of $550 million. Underwriters have a 30-day option to purchase up to 4,714,285 additional shares, which would bring total gross proceeds to $632.5 million.

• Net Proceeds and Use of Funds

  After underwriting discounts ($1.05/share) and estimated expenses, net proceeds are approximately $516.0 million (or $593.5 million if the greenshoe is exercised). Funds will support R&D for product candidates, working capital, and potential in-licensing or acquisitions.

• Immediate Dilution of $14.84 Per Share

  New investors will experience immediate dilution of $14.84 per share based on the as-adjusted net tangible book value of $2.66 per share as of March 31, 2026. The offering increases shares outstanding by about 10% (to ~342.2 million shares).

• Lock-Up Agreements in Place

  Directors, executive officers, and certain securityholders have agreed to a 60-day lock-up period, subject to customary exceptions. The company also agreed not to sell shares under its existing $200 million ATM program for at least 30 days (or until the greenshoe is exercised in full).

auto_awesomeAnalysis · ERAS · Life Sciences

Erasca is raising $550 million (up to $632.5 million with the greenshoe) in a follow-on offering priced at $17.50 per share, a modest 2.2% discount to the July 13 close of $17.90. The deal comes just one day after the company announced updated positive Phase 1 data for its lead asset ERAS-0015 and a $500 million offering plan. Pricing near the market suggests strong institutional demand, despite recent legal headwinds and a patient death disclosure. However, the offering will dilute existing shareholders by roughly 10% (31.4 million new shares on ~311 million outstanding), and the company still has a $200 million ATM program available. Proceeds are earmarked for R&D and general corporate purposes, extending the cash runway as Erasca advances its pipeline toward registration-enabling trials.